Evaluation of CNTY-101, a CD19-targeted CAR iNK Cell Therapy, in Refractory Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and Diffuse Cutaneous Systemic Sclerosis

The primary objective of the CALiPSO-1 Study is to evaluate the efficacy and safety of **CNTY-101**, a CD19-targeted CAR iNK cell product, in participants with refractory B cell-mediated autoimmune diseases, specifically **systemic lupus erythematosus (SLE)**, **lupus nephritis (LN)**, **idiopathic inflammatory myopathy (IIM)**, and **diffuse cutaneous systemic sclerosis (DcSSc)**. The clinical relevance of this study lies in its potential to offer a novel therapeutic option for patients with these challenging conditions, which are often resistant to conventional treatments. The study aims to address the unmet medical need for effective therapies in these patient populations.

The clinical trial involves a total of **24 participants** diagnosed with **systemic lupus erythematosus (SLE)**, **lupus nephritis (LN)**, **idiopathic inflammatory myopathy (IIM)**, and **diffuse cutaneous systemic sclerosis (DcSSc)**. The study population includes both male and female subjects, with an age range that encompasses both adults and adolescents. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The selection process aimed to ensure a representative sample of individuals affected by these conditions, without further details on the selection methodology.

The clinical trial is designed to evaluate the efficacy and safety of a **CD19-targeted CAR iNK cell product** in participants with refractory B cell-mediated autoimmune diseases, specifically **systemic lupus erythematosus**, **lupus nephritis**, **idiopathic inflammatory myopathy**, and **diffuse cutaneous systemic sclerosis**. This is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is July 28, 2025, with an anticipated end date of August 29, 2040. The trial will involve multiple study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Participants who meet the inclusion criteria will be randomized to receive either the investigational product or a control. Follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess the treatment's efficacy, and record any adverse events. The end-of-study visit will occur at the conclusion of the treatment period to gather final data and ensure participant safety.

The expected length of participant involvement will vary depending on individual response and the overall trial timeline, but it is anticipated to span several years. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or non-compliance with study protocols. Participants will be closely monitored throughout the trial to ensure adherence to the study design and to maintain the integrity of the data collected. The trial aims to provide valuable insights into the potential therapeutic benefits of the investigational product for individuals with these challenging autoimmune conditions.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on July 28, 2025, with an estimated completion date of August 29, 2040. The efficacy assessment will be conducted using predefined primary and secondary endpoints, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate measurement and analysis of efficacy parameters. The schedule for measuring and collecting data will be aligned with the trial's protocol, ensuring consistency and reliability in the results. The analysis will be conducted using scientifically validated methods appropriate for a Phase 3 trial, ensuring that the findings are robust and clinically meaningful. The trial's design and execution will adhere to regulatory standards and guidelines to ensure the integrity and validity of the efficacy assessments.